Scarica l'app Stockscreener
7.6317
0.33%
-0.0283
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BCRX Giù?
Forum
Previsione
Precedente Chiudi:
$7.66
Aprire:
$7.68
Volume 24 ore:
776.66K
Relative Volume:
0.16
Capitalizzazione di mercato:
$1.61B
Reddito:
$557.51M
Utile/perdita netta:
$-35.71M
Rapporto P/E:
-42.40
EPS:
-0.18
Flusso di cassa netto:
$15.50M
1 W Prestazione:
-2.80%
1M Prestazione:
+5.60%
6M Prestazione:
-28.04%
1 anno Prestazione:
-2.86%
Intervallo 1D:
$7.54
$7.77
Intervallo di 1 settimana:
$7.45
$7.9797
Portata 52W:
$6.00
$11.31
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Nome
Biocryst Pharmaceuticals Inc
Settore
Telefono
919-859-1302
Indirizzo
4505 EMPEROR BOULEVARD, DURHAM, NC
Confronta BCRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
7.635 | 1.61B | 557.51M | -35.71M | 15.50M | -0.18 |
|
ZTS
Zoetis Inc
|
118.39 | 52.03B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.50 | 45.40B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.63 | 42.13B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.71 | 34.19B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
484.33 | 20.88B | 3.08B | 1.24B | 1.07B | 25.61 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-15 | Ripresa | TD Cowen | Buy |
| 2025-10-01 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-02-25 | Iniziato | Wedbush | Outperform |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-09-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-13 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-02-22 | Aggiornamento | Needham | Hold → Buy |
| 2022-11-02 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2022-08-05 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-08-05 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-04-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2022-04-11 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-12-10 | Iniziato | Oppenheimer | Outperform |
| 2021-08-06 | Downgrade | Jefferies | Buy → Hold |
| 2021-08-03 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-03-01 | Iniziato | Cowen | Outperform |
| 2020-09-29 | Ripresa | JP Morgan | Overweight |
| 2020-06-17 | Iniziato | BTIG Research | Neutral |
| 2020-05-05 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-11-15 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | Ripresa | Piper Jaffray | Overweight |
| 2018-08-08 | Ripresa | JP Morgan | Overweight |
| 2018-07-17 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | Iniziato | Seaport Global Securities | Neutral |
| 2018-01-02 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | Iniziato | Barclays | Equal Weight |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2017-09-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2017-02-16 | Iniziato | Ladenburg Thalmann | Buy |
| 2016-08-12 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | Reiterato | FBR Capital | Outperform |
| 2016-02-09 | Downgrade | JP Morgan | Overweight → Neutral |
| 2016-02-09 | Downgrade | Needham | Buy → Hold |
Mostra tutto
Biocryst Pharmaceuticals Inc Borsa (BCRX) Ultime notizie
BioCryst Pharmaceuticals announces board chair transition following retirement notice By Investing.com - Investing.com South Africa
BioCryst Pharmaceuticals announces board chair transition following retirement notice - Investing.com India
BioCryst Announces Board Chair Transition Plan - TipRanks
Hood River Capital Management LLC Buys New Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Trading Action: Can BioCryst Pharmaceuticals Inc stock hit analyst price targetsJuly 2025 Catalysts & Trade Opportunity Analysis Reports - BỘ NỘI VỤ
BioCryst Pharmaceuticals, Inc. $BCRX Shares Bought by Jump Financial LLC - MarketBeat
JPMorgan Chase & Co. Grows Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
BioCryst Pharmaceuticals, Inc. $BCRX Shares Acquired by Russell Investments Group Ltd. - MarketBeat
Would You Still Hold BioCryst Pharmaceuticals Stock If It Fell 30%? - Trefis
BioCryst Pharmaceuticals, Inc. $BCRX Position Increased by Arrowstreet Capital Limited Partnership - MarketBeat
BioCryst Pharmaceuticals Inc. (BCRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why BioCryst Pharmaceuticals Inc. stock is seen as undervalued2025 Short Interest & Verified Short-Term Trading Plans - Newser
Is BioCryst Pharmaceuticals Inc. stock a good choice for value investorsVolume Spike & Reliable Price Action Trade Plans - Newser
BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Alane Barnes Sells 19,770 Shares - MarketBeat
BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Sells $646,128.40 in Stock - MarketBeat
Insider Selling: BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Sells 50,906 Shares of Stock - MarketBeat
Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals - sharewise.com
BioCryst Pharma (BCRX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Panagora Asset Management Inc. Cuts Stock Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Biocryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
BioCryst (BCRX) Awards Stock Options and RSUs to New Employees - GuruFocus
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
How BioCryst Pharmaceuticals Inc. stock reacts to global recession fearsPortfolio Profit Report & Free Community Consensus Stock Picks - Newser
BioCryst receives antitrust clearance for Astria acquisition By Investing.com - Investing.com Canada
BioCryst’s Ongoing Boost: Buy or Watch? - StocksToTrade
BioCryst Pharmaceuticals Officer Sells Over 161K Shares - TradingView
Officer Barnes Files To Sell 19,770 Of BioCryst Pharmaceuticals Inc [BCRX] - TradingView
BioCryst Pharmaceuticals (BCRX): Valuation Check After Positive APeX-P Pediatric ORLADEYO Trial Update - Yahoo Finance
Biocryst receives early termination of Hart-Scott-Rodino waiting period for Astria acquisition - marketscreener.com
BioCryst Pharmaceuticals-Astria Deal Clears Regulatory Hurdle - marketscreener.com
BioCryst Pharmaceuticals Inc Announces Early HSR Termination for Astria Merger - TradingView
Astria Therapeutics (ATXS) Acquisition Moves Forward with Antitr - GuruFocus
BioCryst receives antitrust clearance for Astria acquisition - Investing.com India
BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition - The Manila Times
BioCryst Pharmaceuticals Announces Early Termination of HSR Waiting Period for Astria Therapeutics Acquisition - Quiver Quantitative
Prudential Financial Inc. Sells 159,975 Shares of BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Is BioCryst Pharmaceuticals Inc. stock resilient to inflation - Newser
Can BioCryst Pharmaceuticals Inc. stock sustain market leadershipJuly 2025 Action & Risk Managed Trade Strategies - Newser
Fisher Asset Management LLC Lowers Stake in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Precision Trading with Biocryst Pharmaceuticals Inc. (BCRX) Risk Zones - news.stocktradersdaily.com
FDA’s docket holds 16 more PDUFA dates by year-end - BioCentury
BioCryst Pharmaceuticals, Inc. $BCRX Shares Purchased by Legal & General Group Plc - MarketBeat
Officer Barnes Files To Sell 91,004 Of BioCryst Pharmaceuticals Inc [BCRX] - TradingView
Vinva Investment Management Ltd Takes $478,000 Position in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
BioCryst to buy Astria Therapeutics for $13 per share (update) - MSN
Elo Mutual Pension Insurance Co Takes Position in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Astria Therapeutics: Updating Target Price, BioCryst Deal Expected To Go Through, Hold - Seeking Alpha
BioCryst Data Highlights Severe Psychosocial Burden of HAE on Pediatric Patients, Caregivers - Finviz
Jefferies Financial Group Inc. Makes New Investment in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Geode Capital Management LLC Has $45.30 Million Stock Position in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Segall Bryant & Hamill LLC Decreases Stake in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Biocryst Pharmaceuticals Inc Azioni (BCRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.31%
0.66%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):